CompletedPHASE1, PHASE2NCT03519711
A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia
Studying Disorder of phenylalanin or tyrosine metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PTC Therapeutics
- Principal Investigator
- Neil Smith, PharmDCensa Pharmaceuticals
- Intervention
- PTC923(drug)
- Enrollment
- 8 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2020
Study locations (4)
- University of Minnesota, Minneapolis, Minnesota, United States
- UT Southwestern, Dallas, Texas, United States
- University of Utah Hospital, Salt Lake City, Utah, United States
- Marshfield Clinic, Marshfield, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03519711 on ClinicalTrials.gov